Treatment-emergent adverse events in the RECAP and CAPACITY studies
| RECAP# | CAPACITY¶ | |
| Nausea | 30.0 | 36.2 |
| Discontinuation | 1.3 | 1.4 |
| Diarrhoea | 22 | 28.7 |
| Discontinuation | 0.5 | 0 |
| Photosensitivity | 8.8 | 12.2 |
| Discontinuation | 0.3 | 0.9 |
| Rash | 13.3 | 32.2 |
| Discontinuation | 1.2 | 1.4 |
Data are presented as %. CAPACITY: Clinical Studies Assessing Pirfenidone in Idiopathic Pulmonary Fibrosis: Research on Efficacy and Safety Outcomes.#: n=603; ¶: n=345. Data from [10].